Plant glycans: friend or foe in vaccine development?

Bosch, Dirk; Schots, A.

doi:10.1586/erv.10.83

Cited by 71 publications

(38 citation statements)

References 64 publications

(57 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, these glycans have been linked to allergenicity of various plant-derived glycoproteins (55). A study by Jin et al has shown that rabbits immunized with the plant-produced xylose-and fucose-carrying MAb 2G12 (formulated with incomplete Freund adjuvant) induced a humoral immune response to the plant N-glycans, and serum IgE from allergic patients bound to the fucosylated glycan structures (56).…”

Section: Discussionmentioning

confidence: 99%

Efficient Single Tobamoviral Vector-Based Bioproduction of Broadly Neutralizing Anti-HIV-1 Monoclonal Antibody VRC01 in Nicotiana benthamiana Plants and Utility of VRC01 in Combination Microbicides

Hamorsky

Grooms-Williams

Husk

et al. 2013

Antimicrob Agents Chemother

View full text Add to dashboard Cite

bBroadly neutralizing monoclonal antibodies (bnMAbs) may offer powerful tools for HIV-1 preexposure prophylaxis, such as topical microbicides. However, this option is hampered due to expensive MAb biomanufacturing based on mammalian cell culture. To address this issue, we developed a new production system for bnMAb VRC01 in Nicotiana benthamiana plants using a tobamovirus replicon vector. Unlike conventional two-vector-based expression, this system was designed to overexpress fulllength IgG1 from a single polypeptide by means of kex2p-like enzyme recognition sites introduced between the heavy and light chains. An enzyme-linked immunosorbent assay (ELISA) revealed that gp120-binding VRC01 IgG1 was maximally accumulated on 5 to 7 days following vector inoculation, yielding ϳ150 mg of the bnMAb per kg of fresh leaf material. The plant-made VRC01 (VRC01p) was efficiently purified by protein A affinity followed by hydrophobic-interaction chromatography. ELISA, surface plasmon resonance, and an HIV-1 neutralization assay demonstrated that VRC01p has gp120-binding affinity and HIV-1-neutralization capacity virtually identical to the human-cell-produced counterpart. To advance VRC01p's use in topical microbicides, we analyzed combinations of the bnMAb with other microbicide candidates holding distinct antiviral mechanisms in an HIV-1 neutralization assay. VRC01p exhibited clear synergy with the antiviral lectin griffithsin, the CCR5 antagonist maraviroc, and the reverse transcriptase inhibitor tenofovir in multiple CCR5-tropic HIV-1 strains from clades A, B, and C. In summary, VRC01p is amenable to robust, rapid, and large-scale production and may be developed as an active component in combination microbicides with other anti-HIV agents such as antiviral lectins, CCR5 antagonists, and reverse transcriptase inhibitors.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficient Single Tobamoviral Vector-Based Bioproduction of Broadly Neutralizing Anti-HIV-1 Monoclonal Antibody VRC01 in Nicotiana benthamiana Plants and Utility of VRC01 in Combination Microbicides

Hamorsky

Grooms-Williams

Husk

et al. 2013

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…Plants have demonstrated the ability to yield highly homogenous glycan profiles on recombinant proteins after glycoengineering. Highly homogeneously glycosylated antibodies (with ~80% galactosylated structures) can be isolated from glycoengineered Nicotiana benthamiana, comparing favorably with the Chinese hamster ovary cell line production of the same antibody and suggesting that plants are excellent production hosts for glycosylated subunit vaccines yielding homogeneous products [3].…”

Section: Franco M Buonaguromentioning

confidence: 98%

PharmaPlant: the new frontier in vaccines

Buonaguro¹,

Butler-Ransohoff

2010

Expert Review of Vaccines

View full text Add to dashboard Cite

“…In particular, plants can be applied for the production of recombinant vaccines. Under the concept of plant-based vaccines, plant tissues can serve as a low cost source of target antigens having high biosynthetic capacity to produce complex proteins, although differential glycosylation may lead to modifications on the immunogenic properties [41]. Plant biomass produced in bioreactors or green houses serve as the expression host of recombinant antigens.…”

Section: Plant-based Vaccinesmentioning

confidence: 99%

An overview of tuberculosis plant-derived vaccines

Rosales‐Mendoza¹,

Ríos-Huerta²,

Angulo³

2015

Expert Review of Vaccines

View full text Add to dashboard Cite

Tuberculosis (TB) is a leading fatal infectious disease to which the current BCG vaccine has a questionable efficacy in adults. Thus, the development of improved vaccines against TB is needed. In addition, decreasing the cost of vaccine formulations is required for broader vaccination coverage through global vaccination programs. In this regard, the use of plants as biofactories and delivery vehicles of TB vaccines has been researched over the last decade. These studies are systematically analyzed in the present review and placed in perspective. It is considered that substantial preclinical trials are still required to address improvements in expression levels as well as immunological data. Approaches for testing additional antigenic configurations with higher yields and improved immunogenic properties are also discussed.

show abstract

Plant glycans: friend or foe in vaccine development?

Cited by 71 publications

References 64 publications

Efficient Single Tobamoviral Vector-Based Bioproduction of Broadly Neutralizing Anti-HIV-1 Monoclonal Antibody VRC01 in Nicotiana benthamiana Plants and Utility of VRC01 in Combination Microbicides

Efficient Single Tobamoviral Vector-Based Bioproduction of Broadly Neutralizing Anti-HIV-1 Monoclonal Antibody VRC01 in Nicotiana benthamiana Plants and Utility of VRC01 in Combination Microbicides

PharmaPlant: the new frontier in vaccines

An overview of tuberculosis plant-derived vaccines

Contact Info

Product

Resources

About